English
Bulgarian
Chinese (Simplified)
Croatian
Czech
Danish
Dutch
Finnish
French
German
Greek
Hebrew
Hindi
Indonesian
Italian
Japanese
Korean
Macedonian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swedish
Thai
Turkish
Vietnamese
Error
The requested page couldn't be found.
An error has occurred while processing your request. This could be caused by any of the following:
- An out-of-date bookmark/favourite
- A mistyped address
- A search engine that has an out-of-date listing for this site
- You do not have access to this page
Please use our site navigation to find what you are looking for, otherwise please feel free to contact us via the contact us page.
Under Construction
This page is currently under construction
Privacy Policy
We are pleased to welcome you to our website www.cml-foundation.org
In the context of our privacy policy, we would like to provide you with an overview of the technical data which are collected and which, in a broader sense, may have personal relevance and the direct personal data that we receive from you and how we handle it.
Should questions remain unanswered or were answered only insufficiently, we are happy to address them. For questions about data processing, please contact us via the following email address: info@cml-foundation.org
Responsible in accordance with the General Data Protection Regulation:
Official registered address:
International CML Foundation
20 Eversley Road
Bexhill-On-Sea
East Sussex
TN40 1HE - UK
E-Mail: info@cml-foundation.org
Entering our website (technical data with personal reference):
To provide the service of a web service - the presentation of the content of our website in the browser on your computer, tablet or smartphone - temporary specific technical details must be stored by you.
The following data is logged:
- IP address
- Timestamp of access,
- Requested resource
- Status
- Transferred amount of data and
- Duration of data transmission
- Origin of your page request
- Name and version of the browser software
The collected data are recorded in so-called server log files. The collected data allow statistical evaluations that ensure the proper function of the website.
Should we obtain concrete indications for unlawful use, we will also process the collected data (as described above) for misuse detection and tracking.
Usually, these server logs are deleted after 8 days.
This expanded analysis of technical data with reference to individuals is reflected in Art. 6 para. 1 lit. f DSGVO.
Transferred personal data
We only store the personal information that you provide us with. (Art. 6 para. 1 lit. a GDPR)
We only collect data that are necessary to provide you with the service (eg newsletter, access to a forum, etc.) your requested or answer to your inquirey (e.g. via our contact form or by email, etc.).
The forms for registration or contact are sperated into necessary information (marked as "required") and voluntary information.
The personal data provided in this context will exclusively be used for the purpose intended by you.
If you get in touch with us
This data will not be used for other purposes and deleted upon fulfillment of the purpose.
You would like to receive regular information (newsletter)
In order for us to be able to send you the newsletter, we need a valid email address from you. The registration takes place in two steps (double-opt-in):
You access our website at the appropriate form and enter your email address.
You will then receive a validation email from us. The link contained must be clicked on in order to complete the registration.
The information you provide and the validity of the registration will be used exclusively for the service "Newsletter".
You want to join a forum and / or leave comments:
For certain areas on our website you need to register. With the process of registration we receive from you some personal data, which we use exclusively for the service forum / comment / personal area.
As evidence of consent to the processing of the personal data provided, the date, time and IP address are stored with the registration.
In the personal area you also have the opportunity to change your own data or delete it.
Forum posts and comments are published with your chosen username and posting date.
You want subscriptions to your comments:
You have the option to subscribe to both the entire website and follow-up comments on your post. You will receive an email to confirm your email address. Besides this, no further data will be collected. You can unsubscribe at any time.
We use cookies on our website:
This website uses cookies to make your website visit as pleasant as possible. A cookie is a small piece of information that is stored locally on your computer.
We use two categories of cookies:
a) technically necessary cookies
This website uses cookies to make your website visit as pleasant as possible. A cookie is a small piece of information that is stored locally on your computer.
We use two categories of cookies:
a) technically necessary cookies
Each time you visit our website, a unique session number is assigned for this call. This cookie should help that the communication between web server and your browser works smoothly and z. For example, registration, registration and ordering processes are processed correctly.
b) Function cookies
In order to be able to save certain preferences you have made on our website, we use functional cookies. These presets will be recalled the next time you visit our website and allow you to: For example, you can quickly navigate to specific content on our website or remember login information for closed areas on the site.
Preferences in the browser:
You have the option to prevent the storage of cookies on your device by making the appropriate settings in your browser. These presets (keyword "Do not Track" etc.) are respected by us in any case
However, you may not be able to access all features of this website without restriction if your browser does not allow cookies.
Furthermore, we do not use any methods that include automated decision making including profiling i. P. V. Provide or support Article 22 (1) and (4) GDPR.
We also do not rely on third party data sources to identify our visitors.
Use of PlugIns Social Networks:
In order to continue to offer you the opportunity to provide feedback to social media regarding our website, we use social media buttons from the shariff project of c't Computerzeitung.
In particular, the usual share buttons will be replaced by the following providers:
- Facebook (Facebook Inc., 1601 S. California Ave., Palo Alto, CA 94304 USA)
- Twitter (Twitter Inc., 1355 Market St., Suite 900, San Francisco, CA 94103, USA)
- Google+ (Google Inc, 1600 Amphitheater Parkway, Mountain View, CA 94043, USA)
- YouTube (YouTube, LLC, 901 Cherry Ave., San Bruno, CA 94066, USA)
- Xing (XING AG, Gänsemarkt 43, 20354 Hamburg, Germany)
- LinkedIn (LinkedIn Ireland Unlimited Company, Wilton Place, Dublin 2, Ireland)
The following text was taken directly from the c't website on 27.11.2014
https://www.heise.de/ct/artikel/Shariff-Social-Media-Buttons-mit-Datenschutz-2467514.html), um die Funktionsweise der Shariff-PlugIns zu erklären: ">(Link: https://www.heise.de/ct/artikel/Shariff-Social-Media-Buttons-with-Privacy-2467514.html) to explain how the Shariff plug-ins work:
"The usual social media buttons transfer the user data to Facebook & Co. for every page view and provide the social networks with exact information about their surfing behavior (user tracking). You do not have to be logged in to be a member of the network. On the other hand, a Shariff button does not establish direct contact between social network and visitors until the latter actively clicks on the share button.
This way, Shariff prevents you from leaving a digital trail on every page you visit and improves privacy. Then you can like, + 1en or tweet - the social network does not get more information.
Thanks to Shariff, the display of "Likes" comes from the operator of the page with the buttons. Because Shariff is involved by the webmaster, you do not have to do anything else as a visitor. "
Use of videos from YouTube and Vimeo:
In part, we use third-party servers in our offering to play videos of events, training, or to better illustrate issues.
The third-party vendors are:
YouTube
(YouTube, LLC, 901 Cherry Ave., San Bruno, CA 94066, USA)
Vimeo
(Vimeo, LLC, 555 West 18th Street, NY, New York 10011, USA)
When you visit a page that has a video attached to it, it will connect to the servers of YouTube or Vimeo. It tells you which page you are calling. At the start of the video, cookies are used, which provide information about your user behavior.
You can prevent this by setting the appropriate settings in your browser to block cookies.
Google also offers the option of permanently installing a plug-in for the most popular browsers, which prevent tracking by Google Analytics. To do this, go to the following page:
https://tools.google.com/dlpage/gaoptout?hl=de
Duration of storage of personal data:
Your personal data will be stored by us as long as we answer a request or you use the appropriate service / service. With a notice or notice from you, your personal data, if possible, will be deleted immediately.
Otherwise, the data will be disabled and, if technically possible, routinely deleted or anonymized.
Irrespective of this, other legal requirements may require that personal data be retained for a longer period of time.
Duration of saving posts, comments, articles on our website:
Posts, comments, articles and the like published on our site will be retained after your departure. However, certain characteristics that allow a conclusion to the person are withdrawn or anonymized by other measures.
Transfer of personal data to third parties:
We do not share your data.
Data processing outside the European Union:
The servers used for the internet presence are all located in the Federal Republic of Germany.
Your rights regarding the processing of personal data:
Right:
You can at any time exercise your right to request information from us, which personal data we have stored by you (Art. 15 GDPR).
Right to correct incorrect data:
If personal data have been incorrectly collected from you or are no longer correct, we will immediately comply with your right of correction
(Art. 16 GDPR).
Right to cancellation:
You have the right to ask us for an immediate deletion if the personal data are no longer processed for the original purpose or are no longer necessary (Art. 17 GDPR).
You may also exercise the right to cancellation if you have revoked your consent and there is no other legal basis for the processing.
Right to restriction of processing and opposition to processing:
You have the right to request a limitation of the processing of your data (Art. 18 and Art. 21 (1) GDPR)
Right to data portability:
If you want to take your data with you, you have the right of data portability. We will make the relevant data available to you in a standard, structured and machine-readable format or hand it over directly to another person responsible (Art. 20 GDPR)
Use the email address to tell us your request:
info@cml-foundation.org
Your right of appeal to the competent supervisory authority:
If all previous attempts have not brought a satisfactory solution to your concern, then you have the right to complain to the regulatory authority responsible for us.
CML Publications 2017
CML Publications 2017
| Clinical Publications | Scientific Publications |
| December 2017 | |
| Treatment-free remission in CML: who, how, and why? (Mahon FX. Hematology Am Soc Hematol Educ Program, December 2017) |
Exosomes derived from imatinib-resistant chronic myeloid leukemia cells mediate a horizontal transfer of drug-resistant trait by delivering miR-365 (Min QH et al. Exp Cell Res, December 2017) (epub ahead of print) |
| Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy (Barber MC et al. Hematology Am Soc Hematol Educ Program, December 2017) |
Ecotopic viral integration site 1 (EVL1) transcriptionally targets talin 1 (TLN1) and upregulates its expression in chronic myeloid leukemia (Halder A et al. Leuk Lymphoma, December 2017) (epub ahead of print) |
| Novel approaches to therapy in CML (Bhatia R et al. Hematology Am Soc Hematol Educ Program, December 2017) |
C1206, a novel curcumin derivate, potently inhibits Hsp90 and human chronic myeloid leukemia cells in vitro (Fan YL et al. Acta Pharmacol, December 2017) (epub ahead of print) |
| Front-line treatment options for chronic-phase chronic myeloid leukemia (Shah NP et al. J Clin Oncol, December 2017) (epub ahead of print) |
Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib (Giallongo C et al. J Cell Mol Med, December 2017) (epub ahead of print) |
| Mechanisms of resistance to targeted therapies in chronic myeloid leukemia (Lussana F et al. Handb Exp Pharmacol, December 2017) (epub ahead of print) |
Controversies regarding use of myeloid growth factors in leukemia (Poston JN et al. J Natl Compr Canc Netw, December 2017) |
| Management of chronic myeloid leukemia in the setting of pregnancy: when is leukocytapharesis appropriate? A case report and review of the literature (Staley EM et al. Transfusion, December 2017) (epub ahead of print) |
|
|
Atypcial chronic myeloid leukemia: a rare entity with management challenges (Dhakal P et al. Future Oncol, December 2017)(epub ahead of print) |
|
|
Successful ovarian stimulation for fertility preservation in a patient with chronic myeloid leukemia: switch from nilotinib to interferon-alpha |
|
| November 2017 | |
| Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: Results from the randomized BEFORE trial (Cortes JE et al. J Clin Oncol, November 2017) (epub ahead of print) |
Targeting BCR-ABL-independent TKI resistance in chronic myeloid leukemia by mTOR and authophagy inhibition (Mitchell R et al. J Natl. Cancer Inst, November 2017) (epub ahead of print) |
| Bosutinib more effective than imatinib in CML (Gourd E. Lancet Oncol, November 2017) (epub ahead of print) |
Off-target effect of imatinib and nilotinib on human vitamin D3 metabolism |
| Clinical efficacy and safety of first-line dasatinib therapy and the relevance of velocity of BCR-ABL1 transcript decline for achievement of molecular chronic-phase chronic myeloid leukemia: Report from the Juntendo Yamanashi Cooperative Study Group (Takaku T et al. Oncology, November 2017) (epub ahead of print) |
|
| Immature CML cells implement a BMP autocrine loop to escape TKI treatment (Grockowiak E et al. Blood, November 2017) |
|
| Prognostic relevance of CCAs/Ph- CML settled (Hehlmann R et al. Blood, November 2017) |
|
|
Off-target effect of imatinib and nilotinib on human vitamin D3 metabolism |
|
| Chk1 inhibitors overcome imatinib resistance in chronic myeloid leukemia cells (Lei H et al. Leuk Res, November 2017) (epub ahead of print) |
|
| Altered intracellular signaling by imatinib increases the anti-cancer effects of tyrosine kinase inhibitors in CML cells (Hirao T et al. Cancer Sci, November 2017) (epub ahead of print) |
|
| October 2017 | |
| Long-term patient-reported outcomes from an open-label safety and efficacy study on bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy (Kantarjian HM et al. Cancer, October 2017) (epub ahead of print) |
Transgenic expression of human cytokines in immunodeficient mice does not facilitate myeloid expansion of BCR-ABL1 transduces human cord blood cells (Askmyr M et al. PLoS One, October 2017) |
| How I manage relapse of chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy (Rea D et al. Br J Haematol, October 2017) (epub ahead of print) |
Micro RNA-7 inhibits cell proliferation of chronic myeloid leukemia and sensitizes it to imatinib in vitro (Jiang MJ et al. Biochem Biophys Res Comm, October 2017) (epub ahead of print) |
| Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting (Boddu P et al. Leuk Lymphoma, October 2017) (epub ahead of print) |
Balaglitazone reverses P-glycoprotein-mediated multidrug resistance via upregulation of PTEN in a PPARy-dependent manner in leukemia cells (Yousefi B et al. Tumour Biol, October 2017) |
| Effects of bosutinib treatment on renal function in patients with Philadelphia chromosome-positive leukemias (Cortes JE et al. Clin Lymphoma Myeloma Leuk, October 2017) |
Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors (Alhuraiji A et al. Am J Hematol, October 2017) (epub ahead of print) |
| Dasatinib cessation after deep molecular response exceeding 2 years, and NK cell transition during dasatinib consolidation (Kumagai T et al. Cancer Sci, October 2017) (epub ahead of print) |
Membrane perturbation through novel cell-penetrating peptides influences intracellular accumulation of imatinib mesylate in CML cells (Mukherjee D et al. Cell Biol Toxicol, October 2017) (epub ahead of print) |
|
Physicians’ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients |
Absolute bioavailability of bosutinib in healthy subjects from an open-label randomized, 2-period crossover study |
| Pleural effusion and molecular response in dasatinib treated chronic myeloid leukemia patients in a real-life Italian multicenter series (Iurlo A et al. Ann Hematol, October 2017) (epub ahead of print) |
Synergistic antiproliferative activity of the RAD51 inhibitor IBR2 with inhibitors of receptor tyrosine kinases and microtubule protein (Ferguson PJ et al. J Pharmacol Exp Ther, October 2017) (epub ahead of print) |
|
First-line therapy for chronic phase CML: selecting the optimal BCR-ABL-1-targeted TKI |
|
|
Sudden blast phase in chronic myeloid leukemia developed during nilotinib therapy after major molecular response was achieved |
|
|
The efficacy of reduced-dose dasatinib as a subsequent therapy in patients with chronic myeloid leukemia in the chronic phase: The LD-CML study of the Kanto CML Study Group |
|
| September 2017 | |
| Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase myeloid leukemia: the JALSG-STIM213 study (Takahashi N et al. Int J Hematol, September 2017) (epub ahead of print) |
High BCR-ABL/Gusis levels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib (Vigneri P et al. Clin Cancer Res, September 2017) |
| Rapid reduction of BCR-ABL1 transcript predicts deep molecular response in dasatinib-treated chronic-phase chronic myeloid leukemia patients (Murai K et al. Eur J Haematol, September 2017) (epub ahead of print) |
Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells (Kuntz EM et al. Nat Med, September 2017) (epub ahead of print) |
| Expression differences of genes in the PI3K/AKT, WNT/b-catenin, SHH, NOTCH and MAPK signaling pathways in CD34+ hematopoietic cells obtained from chronic-phase patients with chronic myeloid leukemia and from healthy controls (de Cássia Viu Carrara R et al. Clin Tranl Oncol, Sept. 2017) (epub ahead of print) |
|
|
A method for next-generation sequencing of paired diagnostic and remission samples to detect mitochondrial DNA mutations associated with leukemia |
|
|
Diagnostic and prognostic cytogenetics of chronic myeloid leukemia: an update |
|
| August 2017 | |
| The safety of bosutinib for the treatment of chronic myeloid leukemia (Kong JH et al. Expert Opin Drug Saf, August 2017) (epub ahead of print) |
CT-721, a potent BCR-ABL inhibitor, exhibits excellent in vitro and in vivo efficacy in the treatment of chronic myeloid leukemia (Sun Y et al. J Cancer, August 2017) |
| Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia (Assi R et al. Clin Lymphoma Myeloma Leuk, August 2017) (epub ahead of print) |
A new mechanism of resistance to ABL1 tyrosine kinase inhibitors in a BCR-ABL1-positive cell line |
| Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML Study IV and impact of non-CML determinants (Hehlmann R et al. Leukemia, August 2017) (epub ahead of print) |
Dasatinib reversibly disrupts endothelial vascular integrity by increasing non-muscle myosin II contractility in a ROCK-dependent manner (Kreutzmann A et al. Clin Cancer Res, August 2017) (epub ahead of print) |
| Impact of imatinib on the fertility of male patients with chronic myelogenous leukaemia in the chronic phase (Chang X et al. Target Oncol, August 2017) (epub ahead of print) |
SHP1 is required for BCR-ABL1-induced hematologic neoplasia (Gu S et al. Leukemia, August 2017) (epub ahead of print) |
|
Vascular adverse events during long-term nilotinib therapy in patients with chronic myeloid leukemia |
Reactive follicular hyperplasia on dasatinib treatment for chronic myeloid leukemia |
|
Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance |
A virtual screening approach for the identification of high affinity small molecules targeting BCR-ABL1 inhibitors for the treatment of chronic myeloid leukemia (Sharda S et al. Curr Top Med Chem, August 2017) |
|
|
Persistent detection of alternatively spliced BCR-ABL variant results in a failure to achieve deep molecular response |
|
|
NCG2D gene polyphormisms are associated with disease control of chronic myeloid leukemia by dasatinib |
|
Sustained molecular response in chronic myeloid leukemia deep responders treated with low dose tyrosine kinase inhibitors |
|
|
Role and mechanisms of decitabine combined in advanced chronic myeloid leukemia cells |
|
| July 2017 | |
| Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients (Jain P et al. Cancer, July 2017) (epub ahead of print) |
Targeting BCR-ABL+ stem/progenitor cells and BCR-ABL-T315l mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex (Chen M et al. Oncotarget, July 2017) |
| Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia (Legros L et al. Cancer, July 2017) (epub ahead of print) |
Association between proteomic profile and molecular response in chronic myeloid leukemic patients (Garrisi VM et al. Leuk Lymphoma, July 2017) (epub ahead of print) |
| Cardiovascular events after exposure to nilotinib in chronic myeloid leukemia: Long-term follow-up (Aghel N et al. Clin Lymphoma Myeloma Leuk, July 2017) (epub ahead of print) |
Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment (Chelysheva E et al. Leuk Lymphoma, July 2017) (epub ahead of print) |
|
How to report adherence to treatment as clinically relevant data-making – a case of CML and TKI |
New tool for monitoring molecular response in patients with chronic myeloid leukemia |
| Treatment-free rmission in patients with chronic myeloid leukemia (Rea D et al. Int J Hematol, July 2017) (epub ahead of print) |
Specific monoclonal antibody against BCR/ABL out-of-frame alternative proteins as diagnostic tool in chronic myelogenous leukemia patients |
|
Nilotinib dose-optimization in newly diagnosed chronic myeloid leukemia in chronic-phase: final results from ENESTxtnd |
Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase CML patients
(Mologni L et al. Am J Hematol, July 2017) |
|
De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial |
Expansion of BCR/ABL1+ cells requires PAK2 but not PAK1
(Edlinger L et al. Br J Haematol, July 2017) |
|
Post-transplant feasibility study of nilotinib prophylaxis for high-risk Philadelphia chromosome positive leukaemia |
PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase |
|
Influence of WHO versus ELN advanced phase chronic myeloid leukemia definitions on overall survival |
Clinical and prognostic significance of e1a2 BCR-ABL transcript subtype in chronic myeloid leukemia |
|
Chronic myeloid leukemia: Global impact from a local laboratory |
Imatinib and nilotinib off-target effects on human NK cells, monocytes, and M2 macrophages |
| Chronic myeloid leukemia: room for improvement? (Baccarani M et al. Haematologica, July 2017) |
|
| June 2017 | |
| Analyses of treatment outcome according to age in patients with chronic myeloid leukemia receiving front-line imatinib therapy (Cojbasic I et al. Clin Lymphoma Myeloma Leuk, June 2017) |
ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure (Marum JE et al. Blood Advances, June 2017) |
| Incidence of second primary malignancies and related myeloid leukemia patients (Gugliotta G et al. Haematologica, June 2017) (epub ahead of print) |
Understanding cancer from the stem cells up |
|
Evaluation of a new flow cytometry based method for detection of BCR-ABL1 fusion protein in chronic myeloid leukemia |
|
|
SHC004-221A1, a novel tyrosine kinase, potently inhibits T315l mutant BCR-ABL in chronic myeloid leukemia |
|
|
A new monoclonal antibody detects downregulation of protein tyrosine phosphatase receptor type y in chronic myeloid leukemia patients |
|
|
|
Genomic profiling of chronic myelogenous leukemia: Basis and clinical approach |
| Chronic myeloid leukemia progenitor cells require autophagy when leaving hypoxia-induced quiescence (Ianniciello A et al. Oncotarget, June 2017) |
|
| May 2017 | |
|
De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial |
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKI’s therapy |
|
Natural killer cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study |
Chronic myeloid leukemia: Immunobiology and novel immunotherapeutic approaches |
|
Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML |
E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in persons with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy |
|
Treatment of chronic myeloid leukemia: assessing risk, monitoring response, and optimizing outcome |
Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic-myeloid leukemia |
| Maternal, fetal and neonatal imatinib levels with treatment of chronic myeloid leukemia in pregnancy (Burwick RM et al. Obstet Gynecol, May 2017) |
Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib (Gullaksen SE et al. Haematologica, May 2017) (epub ahead of print) |
|
New drugs and allogeneic hematopoietic stem cell transplantation for haematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment? |
Micro RNA’s that affect the Fanconi Anemia / BRCA pathway are downregulated in imatinib-resistant chronic myeloid leukemia patients without detectable BCR-ABL kinase domain mutations (Yap E et al. Leuk Res, May 2017) (epub ahead of print) |
|
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib |
A novel BCR-ABL1 fusion gene with genetic heterogeneity indicates a good prognosis in a chronic myeloid leukemia case (Zhou F et al. Mol Cytogenet, May 2017) |
|
Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios |
Deregulated expression of MiR-299-3p, miR-494-3p and miR 660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells (Salati S et al. Oncotarget, May 2017) (epub ahead of print) |
|
Running the marathon of chronic myeloid leukemia with no shoes (or without the right shoes) |
A rare e13a3 (b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: The challenges in diagnosis and monitoring minimal residual disease (MRD) (Duan MH et al. Leuk Res, May 2017) (epub ahead of print) |
|
Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcript by imatinib therapy |
BiRC6 mediates imatinib resistance independently of Mcl-1 (Okumu DO et al. PloS One, May 2017) |
|
Clinical impact of pre-transplant use of multiple tyrosine kinase inhibitors on the outcome of allo-HSCT for CML |
Cancer progression by reprogrammed BCAA metabolism in myeloid leukemia (Hattori A et al. Nature, May 2017) |
|
CML in blast crisis: more common than we think? |
Research on the epigenetic regulation mechanism of the PTPN6 gene in advanced chronic myeloid leukemia (Zhang X et al. Br J Haematol, May 2017) (epub ahead of print) |
|
Treating the chronic-phase myeloid leukemia patient: which TKI, when to switch and when to stop? |
Role of NOX2 for leukemic expansion in a murine model of BCR-ABL1+ leukemia (Grauers Wiktorin H et al. Br J Hematol, May 2017) (epub ahead of print) |
|
Are chronic myeloid leukemia patients ready to stop long-term treatment? |
Baseline BCR-ABL1 transcript type of 13a2 and large spleen size are predictors of poor long-term outcomes in chronic phase chronic myeloid leukemia patients who failed to achieve an early molecular response after 3 months of imatinib therapy (Lee SE et al. Leuk Lymphoma, May 2017) (epub ahead of print) |
|
|
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization
(Luatti S et al. Oncotarget, May 2017) (epub ahead of print) |
| Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukaemia treated with nilotinib (Gullaksen SE. Haematologica, May 2017) (epub ahead of print) |
|
| April 2017 | |
| Understanding CML, 1 cell at a time (Radich J et al. Blood, April 2017) |
Decreased Calpain activity in chronic myeloid leukemia impairs apoptosis by increasing Xiap1 in differentiating granulocytes
(Huang W et al. Oncotarget, April 2017) (epub ahead of print) |
|
Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315l mutation |
A novel AHI-1-BCR-ABL-DNM2 complex regulated leukemic properties of primitive CML cells through enhanced cellular endocytosis and ROS-mediated authophagy |
|
TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML
|
Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment |
|
The role of early molecular response in the management of chronic phase CML |
BCR-ABL 1 transcript types showed distinct laboratory characteristics in patients with chronic myeloid leukemia
(Vasconcelos AP et al. Genet Mol Res, April 2017) |
|
Treatment and molecular monitoring update in chronic myeloid leukemia management |
|
|
Impact of age on efficacy and tolerability of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis |
|
|
Association between a cardiovascular disease risk assessment and the molecular response to tyrosine kinase inhibitors in chronic-phase myeloid leukemia patients |
|
| March 2017 | |
| Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia (Hoffmann VS et al. J Cancer Res Clin Oncol, March 2017) |
The SCLtTAxBCR-ABL transgenic mouse model closely reflects the differential effects of dasatinib on normal and malignant hematopoiesis in chronic phase CML patients
|
|
Imatinib discontinuation in chronic myeloid leukemia patients with undetectable BCR-ABL transcript level: |
Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells (Tsubaki M et al. Oncotarget, March 2017) (epub ahead of print) |
| A BCR-ABL1 cutoff of 1,5 % at 3 months, determined by the GeneExpert System, predicts an optimal response in patients with chronic myeloid leukemia (García-Gutiérrez V. et al. PLoS One, March 2017) |
Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo chronic myelogenous leukemia cell growth (Bellavia D et al. Theranostics, March 2017) |
| Elderly patients with chronic myeloid leukemia benefit from a dasatinib dose as low as 20 mg (Itamura H et al. Clin Lymphoma Myeloma Leuk, March 2017) (epub ahead of print) |
Stelletin B induces apoptosis in human chronic myeloid leukemia cells via targeting Pi3K and Stat 5
(Chen Y et al. Oncotarget, March 2017) (epub ahead of print) |
|
Predictive parameters for imatinib failure in patients with chronic myeloid leukemia (Lekovic D et al. Hematology, March 2017) |
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL 1 |
|
Imatinib changed everything |
Is there an immune suveillance against chronic myeloid leukemia? Possibly, but not much |
| Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors (Maiti A et al. Leuk Lymphoma, March 2017) |
With no interaction, knockdown of Apollon and MDR1 reverse the multidrug resistance of human chronic myelogenous leukemia K562/ADM cells |
| Can any patients with chronic myeloid leukemia outside of clinical trial have their tyrosine kinase inhibitors discontinued? (Mauro MJ. Curr Opin Hematol, March 2017) |
MPT0B002, a novel microtube inhibitor downregulates T315l mutant BCR-ABL and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells |
|
Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5 year final report |
Carfilzomib induces leukemia cell apoptosis via inhibiting ELK1/Ki AA1524 (ELK-1/CIP2A) and activating PP2A not related to proteasome inhibition |
|
Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib |
Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia |
|
Treatment and outcome of 2904 CML patients from the EUTOS population-based registry |
p53 modulates the effect of ribosomal S6 kinase 1 (S6K1) cisplatin toxicity in chronic myeloid leukemia cells |
|
Long-term outcomes of imatinib treatment for CML |
Combined inhibition of ß-catenin and BCR-ABL synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo (Zhou H et al. Leukemia, March 2017) (epub ahead of print) |
|
Factors influencing adherence in CML and ways to improvement: Results of a patient-driven survey of 2546 patients in 63 countries |
Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia |
|
Treatment and outcomes of 2904 CML patients from the EUTOS population-based registry |
Measurement of BCR-ABL1 by RT-qPCR in chronic myeloid leukemia: findings from an international EQA Programme |
| Unleasing the Guardian: The targetable BCR-ABL/HAUSP/PML/PTEN Network in chronic myeloid leukemia (Morotti A et al. Curr Drug Targets, March 2017) |
|
The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase inhibitors conferred by the deletion polymorphism in chronic myeloid leukemia (Rauzan M et al. PLoS One, March 2017) |
|
|
|
Blockade of Y177 and and nuclear translocation of BCR-ABL inhibits proliferation and promotes apoptosis in chronic myeloid leukemia cells (Li Q et al. Int J Mol Sci, March 2017) |
| February 2017 | |
| Pleural effusion in Dasatinib-treated patients with chronic myeloid leukemia in chronic phase: Identification and management (Cortes J et al. Clin Lymphoma Myeloma Leuk, February 2017) |
Molecular techniques for the personalised management of patients with chronic myeloid leukemia (Alikian M et al. Biomol Detect Quantif, February 2017) |
| Chronic myeloid leukemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome (Sora F et al. Br J Haematol, February 2017) (epub ahead of print) |
Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression |
| Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemia (Chen Z et al. Blood Cancer J, February 2017) (epub ahead of print) |
Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast crisis chronic myeloid leukemia (Maiti A et al. Leuk Lymphoma, February 2017) (epub ahead of print) |
| Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st subanalysis (Hochhaus A et al. J Cancer Res Clin Oncol, February 2017) (epub ahead of print) |
CobII1 is linked to drug resistance and blastic transformation in chronic myeloid leukemia (Han SH et al. Leukemia, February 2017) (epub ahead of print) |
| Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: Results from the ENESTfreedom Study (Hochhaus A et al. Leukemia, February 2017) (epub ahead of print) |
Up-regulated exosomal miRNA-140-3p in CML patients with musculoskeletal pain associated with discontinuation of tyrosine kinase inhibitors (Asano M et al. Int J Hematol, February 2017) (epub ahead of print) |
| Stopping second-generation TKI's in CML (Laneuville P et al. Blood, February 2017) |
Differential signaling networks of BCR-ABL p210 and p190 kinases in leukemia cells defined by functional proteomics (Reckel et al. Leukemia, February 2017) (epub ahead of print) |
|
Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia? |
Differentiation status of primary chronic myeloid leukemia cells affect sensitivity to BCR-ABL1 inhibitors (Pietarinen PO et al. Oncotarget, February 2017) (epub ahead of print) |
| Smokers with chronic myeloid leukemia are at higher risk of disease progression and premature death (Lauseker M et al. Cancer, February 2017) (epub ahead of print) |
A review of the challenge in measuring and standardizing BCR-ABL1 (Yu S et al. Clin Chem Lab Med, Februar 2017) (epub ahead of print) |
|
Targeted therapies: Remembrance of things past - discontinuation of second-generation TKI therapy for CML |
The JAK2 blocker TG101209 is a potent inhibitor of clonogenic progenitor cell growth in patients with chronic myeloid leukemia (Demyanets S et al. Br J Hematol, February 2017) (epub ahead of print) |
|
Pleural effusion in Dasatinib-treated patients with chronic myeloid leukemia in chronic phase: Identification and management |
The chronic myeloid leukemia stem cell: Stemming the tide of persistence (Holyoake T. et al. Blood, February 2017) |
| Increased peroxisome proliferator-activated receptor-gamma activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells (Wang J et al. Haematologica, February 2017) (epub ahead of print) |
|
| January 2017 | |
| Characterization of patients with chronic myeloid leukemia unresponsive to tyrosine kinase inhibitors who underwent hemoatopoietic stem cell transplantation (Carvalho FR et al. Int J Hematol Stem Cell Res, January 2017) |
Reduced CD62L expression on T cells and increased CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia (Sopper S et al. J Clin Oncol, January 2017) |
| Current approach to the treatment of chronic myeloid leukemia (Pasic I et al. Leuk Res, January 2017) |
CML patients with deep molecular responses to TKI have restored immune effects, decreased PD-1 and immune suppressor |
| Long-term follow-up of the French Stop Imatinib (STIM1) Study in patients with chronic myeloid leukemia (Etienne G. et al. J Clin Oncol, January 2017) |
No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: Results in 1494 patients with chronic myeloid leukemia treated with imatinib |
| Current approach in the treatment of chronic myeloid leukemia (Pasic I et al. Leuk Res, January 2017) (epub ahead of print) |
Modelling predictors of molecular response to frontline imatinib for patients with chronic myeloid leukemia (Banjar H et al. PLoS One, January 2017) |
| Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib (Ailawadhi S. et al. Ther Adv Hematol, January 2017) |
The hypothesis of the human iNKT/innate CD8(+) T-cells axis applied to Cancer: Evidence for a defiency in chronic myeloid leukemia (Jacomet F. et al. Front Immunol, January 2017) |
| Early BCR-ABL1 transcript decline after 1 month of tyrosine kinase inhibitor therapy as an indicator for treatment response in chronic myeloid leukemia (El Missiry M et al. PLoS One, January 2017) |
|
| Induction of p53 suppresses chronic myeloid leukemia (Peterson LF et al. Leuk Lymphoma, January 2017) (epub ahead of print) |
|
|
Epression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML |
|
Dasatinib may be considered a new standard of care for pediatric patients with CML-CP
Dasatinib may be considered a new standard of care for pediatric patients with CML-CP
Madrid, June 2017 -Findings from a large prospective trial with pediatric patients1 suggest that dasatinib provides benefits to children and adolescents in CML-CP who are resistant /intolerant to imatinib.
CML represents less than 3% of all leukemias in children worldwide, but more aggressive disease characteristics have been observed in this patient population.
Currently imatinib is the only approved tyrosine kinase inhibitor in children with CML and no approved therapies are available for children resistant or intolerant to imatinib. "There is an unmet need for safe and effective treatment options for children and adolescents who are resistant or intolerant to imatinib and also for alternative treatment formulations", Dr C. Zwaan opened his presentation at the 22th meeting of the European Hematology Association (EHA) in Madrid.
According to Dr. Zwaan, dasatinib has already shown to be effective in adults with newly diagnosed CML-CP, as well as those resistant/intolerant to imatinib however, "there is almost no published data available in children who are resistant or intolerant to imatinib".
Zwaan presented data from a Phase II open-label, randomized, prospective study conducted in 18 countries. In this large, ongoing prospective trial of pediatric patients with CML-CP, dasatinib was found to be safe and effective as first, or second-line therapy.
Patients aged <18 years were recruited into three separate cohorts: (1) IM-resistant/intolerant CML-CP treated with dasatinib 60 mg/m2 QD, (2) IM-resistant/intolerant CML-AP/BP or Ph+ ALL, and (3) newly diagnosed CML-CP treated with dasatinib 60 mg/m2 or dasatinib 72 mg/m2 powder for oral suspension QD for ≥1 year. Within the imatinib resistant/intolerant group of 29 patients, 25 patients were resistant, 2 intolerant and 2 undetermined.
The primary objectives were MCyR for imatinib resistant/intolerant CML-CP at any time with more than 30% MCyR as the protocol-defined rate of clinical interest and CCyR for newly diagnosed CML-CP at any time with more than 55% CCyR as the protocol-defined rate of clinical interest.
The cumulative rate of MCyR >30% was reached as early as 3 months for IM-resistant/intolerant CML-CP, and a cumulative rate of CCyR >55% was reached as early as 6 months for newly diagnosed CML-CP. Cytogenetic and molecular response continued to increase over time in each cohort. "Early and durable responses to dasatinib were observed, which met the study objectives for both cohorts”, Zwaan summed up the efficacy study results.
The safety profile of dasatinib was comparable to previous reports in adults treated with dasatinib except that no cases of pleural/pericardial effusion or pulmonary arterial hypertension were observed.
Additional advantages include; once-daily dosing and administration with, or without food.
In conclusion, according to Zwaan, this is the largest prospective trial with pediatric patients and dasatinib was found to be a safe and effective treatment for pediatric patients in chronic-phase CML. The safety profile was slightly favourable to adult data with respect to the absence of effusions. “Further investigation is needed to determine whether the reasons for this slightly better safety profile in pediatric patients are due to a better immune system or any other reason”, Zwaan concluded at the end of his presentation.
1. Dasatinib in children and adolescents with chronic myeloid leukemia in chronic phase (CML-CP) from a phase 2 trial, abstract presented by CM Zwaan during the 22nd Congress of the European Hematology Association (EHA), June 22-25, 2017 in Madrid, Spain.
CML Publications 2016
CML Publications 2016
| Clinical Publications | Scientific Publications |
| December 2016 | |
| Response to overexpresssion of ABCB1 as prediction marker for CML: How close we are to translation into clinics? (Eadie LN et al. Leukemia, December 2016) (epub ahead of print) |
CYP2C8 genotype significantly alters imatinib metabolism in chronic myeloid leukemia patients (Barrat DT et al. Clin Pharmacokinet, December 2016) (epub ahead of print) |
| Cardiologist's perspective to the European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukemia (Constance C. et al. Leukemia, December 2016) (epub ahead of print) |
RT-q PCR and RT-Digital PCR: A comparison of different platforms for the evaluation of residual diseease in chronic myeloid leukemia Alikian M et al. Clin Chem, December 2016 (epub ahead of print) |
|
Chronic myeloid leukemia: sequencing of TKI therapies |
Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study (Rousselot P et al. Cancer, December 2016) (epub ahead of print) |
|
Molecular monitoring in chronic myeloid leukemia - how low can you go? |
Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients (Arun AK et al. Int J Lab Hematol, December 2016) (epub ahead of print) |
| Long-term bosutinib for chronic phase myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib (Cortes JE et al. Am J Hematol, December 2016) |
Enhanced targeting of CML stem and progenitor cells by inhibition of porcupine acyltransferase in combination with TKI (Agarwal P et al. Blood, December 2016) (epub ahead of print) |
| The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors (Efficace F et al. Hematology Am Soc Hematol Educ Program, December 2016) |
Response to overexpresssion of ABCB1 as prediction marker for CML: How close we are to translation into clinics? |
|
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia |
|
|
Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy |
|
| November 2016 | |
|
How can I treat atypical CML? |
Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both BCR/Abl-dependent and BCR/Abl-independent mechanisms (Lan X et al. J Hematol Oncol, November 2016) |
| Second line small molecule therapy options for treating chronic myeloid leukemia (Molica M et al. Expert Opin Pharmacotherapy, November 2016) |
Cyclic AMO (cAMP) confers drug resistance against DNA damaging agents via PKAIA in CML cells (Xiao LY et al. Eur J Pharmacol, November 2016) (epub ahead of print) |
| Clinical efficacy of fecal occult blood test and colonoscopy for dasatinib-induced hemorrhagic colitis in CML patients (Nishiwaki S. et al. Blood, November 2016) (epub ahead of print) |
Upreguating miR-146a by pyscion reverses multidrug resistance in human chronic myelogenous leukemia K562/ADM cells (Liu W et al. Am J Cancer Res, November 2016) |
| Standardization of molecular monitoring for chronic myeloid leukemia in Latin America using locally produced secondary cellular calibrators (Ruiz MS et al. Leukemia, November 2016) |
Axl blockade by BGB324 inhibits BCR-ABL tyrosine kinase inhibitor-sensitive and -resistant chronic myeloid leukemia (Ben Batalla et al. Clin Cancer Res, November 2016) (epub ahead of print) |
| How can patient reported outcomes improve patient management in chronic myeloid leukemia? (De Marchi F. et al. Expert Rev Hematol, November 2016) (epub ahead of print) |
Different BCR/ABL protein suppression patterns as a converging trait of chronic myeloid leukemia cell adaptation to energy restriction |
| Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: A systematic review and meta-analysis (Haguet H et al. Expert Opin Drug Saf, November 2016) (epub ahead of print) |
Casiopeina III-Ea, a copper-containing small molecule, inhibits the in viro growth of primitive hematopoietic cells from chronic myeloid leukemia |
| Charlson comorbidity index predicts poor outcome in CML patients treated with tyrosine kinase inhibitor (Uemura M et al. Int J Hematol, November 2016) (epub ahead of print) |
IncRNA UCA1 contributes to imatinib resistance by acting as a ceRNA against miR-16 in chronic myeloid leukemia cells (Xiao Y et al. DNA Cell Biol, November 2016) (epub ahead of print) |
|
A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase
|
Gas6/AXL signaling regulates self-renewal of chronic myelogenous leukemia stem cells by stabilizing ß-catenin
|
| Celecoxib inhibits proliferation and survival of chronic myelogenous leukemia cells via AMPK-dependent regulation of ß-catenin and mTORC 1/2 (Riva B et al. Oncotarget, November 2016) (epub ahead of print) |
|
| Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenetic stimuli (Söderlund S. et al. Leuk Res, Nov, 2016) |
|
| The Rho-ROCK pathway is a new pathological mechanism of innate immune subversion in chronic myeloid leukaemia (Basbous S et al. J Pathol, November 2016) |
|
| Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL1 (35INS) (Berman E et al. Leuk Res, Oct 2016) |
|
| October 2016 | |
|
A population-based study of chronic myeloid leukemia patients treated with imatinib in first-line
|
PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia (Gupta P et al. Cancer Lett, October 2016) (epub ahead of print) |
| Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? (Rosti G. et al. Nat Rev Clin Oncol, October 2016) (epub ahead of print) |
CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression (Tarafdar A. et al. Blood, October 2016) (epub ahead of print) |
| Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship (Koller PB et al. Cancer, October 2016) (epub ahead of print) |
miRNAs in chronic myeloid leukemia: small molecules, essential function (Litwínska Z. et al. Leuk Lymphoma, October 2016) |
|
Current developments in molecular monitoring in chronic myeloid leukemia |
Programmed cell death 4 and BCR-ABL fusion gene expression are negatively correlated in chronic myeloid leukemia (Zhang X et al. Oncol Lett, Oct 2016) |
| September 2016 | |
|
Monitoring and defining early response: Where to draw the line? |
Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition (Scott MT et al. Cancer Discov, Sept 2016) (epub ahead of print) |
|
Discontinuation of TKI therapy and 'functional' cure for CML |
Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor treated CML stem cells (Zhang B et al. Blood, Sept 2016) (epub ahead of print) |
| Management of CML blast crisis (Hehlmann R. et al. Best Pract Res Clin Haematol, September 2016) |
Constitutional t(8;22) (q24;q11.2) that mimics the variant Burkitt-type translocation in Philadelphia chromosomal positiv chronic myeloid leukemia |
| Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidates to ponatinib: an expert opinion (Breccia M et al. Ann Hematol, Sept 2016) (epub ahead of print) |
Micro RNA-139-5p regulates proliferation of hematopoietic progenitors and is repressed during BCR-ABL mediated leukemogenesis (Choi J et al. Blood, Sept. 2016) (epub ahead of print) |
|
Dasatinib in imatinib-resistant or-intolerant chronic-phase chronic myeloid leukemia: 7-year follow-up of study CA180-034 |
Molecular monitoring of chronic myeloid leukemia: present and future
|
|
Ponatinib in the therapy of chronic myeloid leukemia |
Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells (Carter BZ et al. Sci Transl Med, September 2016) |
| August 2016 | |
|
Long-term bosutinib for chronic phase myeloid leukemia after failure of imatinib plus dasatinib and/or bosutinib (epub ahead of print)
|
The BCR-ABL/NF-kB signal transduction network: a long lasting relationship in Philadelphia positiv leukemias
|
| Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome (Iurlo A et al. Oncotarget, August 2016) (epub ahead of print) |
Cepheid xpert monitor platform for the confirmation of BCR-ABL1 is conversion factors for the molecular monitoring of chronic myeloid leukemia |
| Charlson comorbidity index predicts poor outcome in CML patients treated with tyrosine kinase inhibitor (Uemura M et al. Int J Hematol, August 2016) (epub ahead of print) |
ABCB1 overexpression is a key inhibitor of resistance to tyrosine kinase inhibitors in CML cell lines (Eadie LN et al. PLoS one, August 2016) |
| In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants. (Soverini S et al. BMC Cancer, August 2016) |
MiR-124-3p/B4GALT1 axis plays an important role in SOCS3-regulated growth and chemo-sensitivity of CML (Liu YX et al. J Hematol Oncol, August 2016) |
| Multiparameter analysis of off-target effects of dasatinib on bone homeostasis in patients with newly diagnosed myelogenous leukemia (Hoehn D. et al. Clin Lymphoma Myeloma Leuk, Aug 2016) |
miR-101 sensitized K562 cell line to imatinib through JAK2 downregulation and inhibition of NF-kB target genes (Farhadi E et al. Tumour Biol, August 2016) (epub ahead of print) |
| A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase (Takahashi K et al. Cancer, Aug 2016) |
|
| When to consider allogeneic transplantation in CML (Radich J, Clin Lymphoma Myeloma Leuk, Aug 2016) |
|
| Imatinib intolerance is associated with blastic phase development in Philadelphia chromosome-positive chronic myeloid leukemia (Ángeles-Velázquez JL. Clin Lymphoma Myeloma Leuk, August 2016) |
|
| July 2016 | |
| Summary of the published Indian data on chronic myeloid leukemia (Singhal MK et al. South Asian J Cancer, Jul-Sept, 2016) |
A role for FOX01 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia (Wagle M et al. Leukemia, July 2016) |
| Pattern of chronic myeloid leukemia in the imatinib era in a sub-Saharan African setting (Faye BF et al. Ann Hematol, July 2016) (epub ahead of print) |
TP53 codon 72 polymorphism predicts chronic myeloid leukemia susceptibility and treatment outcome (Weich N et al. Blood Celles Mol Dis, July 2016) |
|
A safety evaluation of omacetacine mepesuccinate for the treatment of chronic myeloid leukemia
|
Cooperation of imipramine and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia (Jorgensen KM et al. Oncotarget, July 2016) (epub ahead of print) |
| Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients (Dorer DJ et al. Leuk Res, July 2016) |
What are the challenges in 2016 regarding resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and cancer? (Lewis M et al. Hematol Oncol, July 2016) (epub ahead of print) |
| Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia (Castagnetti F. et al. Haematologica, July 2016) (epub ahead of print) |
Loss of mutL homolog-1 (MLH1) expression promotes acquisition of oncogenic and inhibitor-resistant points mutations in tyrosine kinases (Springuel L. et al. Cell Mol Life Sci, July 2016) (epub ahead of print) |
| Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies (Efficace F. et al. Support Care Cancer, July 2016) (epub ahead of print) |
Influence of CYP3A5*3 and ABCD1 C3435T on clinical outcomes and through plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia (Adeagbo BA et al. J Clin Pharm Ther, July 2016) (epub ahead of print) |
| Changes from imatinib mesylate to second generation tyrosine kinase inhibitors to improve renal impairment with imatinib mesylate in chronic myelogenous leukemia (Hino A et al. Int J Hematol, July 2016) (epub ahead of print) |
The clinical significance of ABCB1 overexpression in predicting outcome of patients undergoing first-line imatinib treatment (Eadie LN et al. Leukemia, July 2016) (epub ahead of print) |
| Advanced phase chronic myeloid leukemia in the TKI era - a report from the Swedish CML register (Söderlund S et al. Eur J Haematol, July 2016) (epub ahead of print) |
Measurement of BCR-ABL1 transcripts on the international scale in the United States: current status and best practices (Arora R et al. Leuk Lymphoma, July 2016) (epub ahead of print) |
| Pregnancy: part of life in chronic myelogenous leukemia (Law AD et al. Leuk Lymphoma, July 2016) (epub ahead of print) |
Impact of ABCD1 1236C> T-2677G> T-3435C> polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib
|
| Deep molecular reponses for treatment-free remission in chronic myeloid leukemia (Dulucq S et al. Cancer Med, July 2016) (epub ahead of print) |
The role for FOX01 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia (Wagle M et al. Leukemia, July 2016) |
| June 2016 | |
|
Incidence of second malignancies of chronic myelid leukemia during treatment with tyrosine kinase inhibitors |
Next-generation sequencing identifies major DNA methylation changes during progression of PH+ chronic myeloid leukemia |
| Discontinuing tyrosine kinase inhibitor therapy in chronic mylogenous leukemia: current understanding and future directions (Bhalla S. et al. Clin Lymphoma Myeloma Leuk, June 2016) (epub ahead of print) |
Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the international scale |
|
Management of pregnant chronic myeloid leukemia patients |
A novel tubulin polymerization inhibitor, MPT0B206, downregulates BCR-ABL expression and induces apoptosis in imatinib-sensitive and imatinib-resistant CML cells |
|
'Real-life' study of imatinib therapy in chronic-phase myeloid leukemia: A novel retrospective observational longitudinal analysis |
Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for chronic myeloid leukemia (CML) |
| Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population (Bower H et al. J Clin Onol, June 2016) (epub ahead of print) |
Drug repurposing for chronic myeloid leukemia: in silicio and in vitro investigation of DrugBank database for allosteric BCR-ABL inhibitors (Singh VK et al. J Biomol Struct Dyn, June 2016) (epub ahead of print) |
| Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML study IV (Miranda et al. Leukemia, June 2016) |
A novel BCR-ABL1 fusion gene identified by next-generation sequencing in chronic myeloid leukemia (Lyn X et al. Mol Cytogenet, June 2016) |
| Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: A population-based cohort study (Dahlén T et al. Ann Intern Med, June 2016) (epub ahead of print) |
MEF2C and CEBPA: Possible co-regulators in chronic myeloid leukemia disease progression (Agatheeswaran S. et al. Int J Biochem Cell Biol, June 2016) (epub ahead of print) |
|
Discontinuing tyrosine kinase inhibitor therapy in chronic mylogenous leukemia: current understanding and future directions |
Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells |
|
Incidence of second malignancies of chronic myelid leukemia during treatment with tyrosine kinase inhibitors (Yin XF et al. Clin Lymphoma Myeloma Leuk, June 2016) (epub ahead of print) |
High IL-7-levels in the bone marrow microenvironment mediate imatinib resistance and predict disease progression in chronic myeloid leukemia |
|
European LeukemiaNet recommendations for the managment and avoidance of adverse events of treatment in chronic myeloid leukemia
|
Unleashing the guardian: the targetable BCR-ABL/HAUSP/PML/PTEN network in CML (Morotti A et al. Curr Drug Targets, June 2016) (epub ahead of print) |
| Next-generation sequencing identifies major DNA methylation changes during progression of PH+ chronic myeloid leukemia (Heller G et al. Leukemia, June 2016) |
|
| Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the international scale (Cross NC et al. Leukemia, June 2016) (epub ahead of print) |
|
| Drug repurposing for chronic myeloid leukemia: in silicio and in vitro investigation of DrugBank database for allosteric BCR-ABL inhibitors (Singh VK et al. J Biomol Struct Dyn, June 2016) (epub ahead of print) |
|
| A novel BCR-ABL1 fusion gene identified by next-generation sequencing in chronic myeloid leukemia (Lyn X et al. Mol Cytogenet, June 2016) |
|
| A novel tubulin polymerization inhibitor, MPT0B206, downregulates BCR-ABL expression and induces apoptosis in imatinib-sensitive and imatinib-resistant CML cells (Chen CW et al. Apoptosis, June 2016) (epub ahed of print) |
|
| MEF2C and CEBPA: Possible co-regulators in chronic myeloid leukemia disease progression (Agatheeswaran S. et al. Int J Biochem Cell Biol, June 2016) (epub ahead of print) |
|
| Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for chronic myeloid leukemia (CML) (Liu F et al. Oncotarget, June 2016) (epub ahead of print) |
|
| May 2016 | |
|
Optimizing the use of TKI's in the management of chronic myelogenous leukemia |
Validation of a rapid one-step high sensitivity real-time quantitative PCR system for detecting major BCR-ABL1 mRNA on an international scale |
|
Setting global standards for stem cell research and clinical translation: The 2016 ISSCR guidelines |
ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome positive cells |
|
Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA 180-034 |
The non-genomic loss of function of tumor suppressors: an essential role in the pathogenesis of chronic myeloid leukemia chronic phase |
|
The treatment of CML at an environment with limited resources |
Next generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia |
| Final 5-year study results of DASASION: The dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial (Cortes JE et al. J Clin Oncol, May 2016) (epub ahead of print) |
The rs61764370 functional variant in the KRAS oncogene is associated with chronic myeloid leukemia risk in women (Gutiérrez-Malacatt H. et al. Asian Pac J Cancer Prev, 2016) |
| Frontline therapy with high-dose imatinib vs. 2nd generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis (Sasaki K et al. Haematologica, May 2016) (epub ahead of print) |
Effect of tyrosine kinase inhibitors of stemness in normal and chronic myeloid leukemia cells (Charaf L et al. Leukemia, May 2016) (epub ahead of print) |
| Management of advanced-phase chronic myelogenous leukemia (Radich JP. J Natl. Compr Canc Netw, May 2016) |
Comparison of branded and generics imatinib plasma concentrations in patients with chronic myelogenous leukemia - unicentric study (Ostojic A. et al. Clin Lymphoma Myeloma Leuk, May2016) |
|
Chronic myeloid leukemia reminiscences and dreams |
Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia (Irvine DA et al. Sci Rep, May2016) |
|
Safety and efficacy of the combination of pegylated interferon-alpha2b and dasatinib in newly diagnosed chronic phase chronic myeloid leukemia patients |
|
| Health-related quality of life outcomes in chronic myleloid leukemia patients treated with second generation tyrosine kinase inhibitors: Do we know enough? (Breccia M et al. Curr Med Res Opin, May 2016) |
|
| April 2016 | |
| Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial (Lipton JH et al. Lancet Oncol, April 2016) (epub ahead of print) |
Identification of CD25 as STAT5 dependent growth regulator of leukemic stem cells in PH+ CML |
| Molecular monitoring of tyrosine kinase inhibitor therapy of chronic myeloid leukemia in China (Jiang Q et al. J Cancer Res Clin Oncol, April 2016) (epub ahead of print) |
Early BCR-ABL reduction is predictive of better event-free survival in patients with newly diagnosed chronic myeloid leukemia treated with any tyrosine kinase inhibitor |
| Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure (Whitely J et al. Curr Med Res Opin, April 2016) (epub ahead of print) |
Modeling BCR-ABL and MLL-AF9 leukemia in a human bone marrow-like scaffold based xenograft model |
| Monitoring disease burden in chronic myeloid leukemia: past, present, and future (Egan D. et al. Am J Hematol, April 2016) (epub ahead of print) |
Quantitative analysis of mutant subclones in chronic myeloid leukemia: comparison of different methodological approaches (Preuner S. et al. Int J Mol Sci, April) |
|
|
Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects Culen M et al. Oncotarget, April 2016 (epub ahead of print) |
|
|
Mtss1 is a critical epigenetically regulated tumor suppressor in CML |
|
The impact of multiple low-level BCR-ABL1 mutations on response to Ponatinib |
|
| Combined population dynamics and entropy modelling supports patients stratification in chronic myeloid leukemia (Brehme M et al. Sci Rep, April 2016) |
|
| March 2016 | |
| Cross-intolerance with dasatinib among imatinib-intolerant patients with chronic phase myeloid leukemia
(Khoury HJ et al. Clin Lymphoma Myeloma Leuk, March 2016) |
Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy (Wang W et al. Blood, March 2016) (epub ahead of print) |
| Hyperhomocysteinemia and high doses of nilotinib favor cardiovascular events in chronic phae chronic myelogenous leukemia patients (Fossard G. et al. Haematologica, March 2016) |
Leukemic stem cell quantification in newly diagnosed chronic myeloid leukamia patients predict response to nilotinib therapy (Thielen N et al. Clin Cancer Res, March 2016) (epub ahead of print) |
|
Increased prevalance of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia |
A role for FOXO1 in BCR-ABL-1 independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia |
| Next generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients (Soverini S. et al. Oncotarget, March 2016) (epub ahead of print) |
The role of Fas-associatd phosphotase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia (Huang W et al. Leukemia, March 2016) (epub ahead of print) |
|
Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity |
Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway (Chen JR et al. Int. J Oncol, March 2016) (epub ahead of print) |
|
Long-term evaluation of cardiac and vascular toxicity in patients with philadelphia chromosome positive leukemias treated with Bosutinib |
Characteristics of BCR-ABL kinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance |
|
Splenic irradication before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study |
Micro RNAs mediated regulation of MAPK signaling pathways in chronic myeloid leukemia |
|
Rotation of nilotinib and imatinib for first-line treatment of chronic myeloid leukemia |
Overexpression of RPS27a contributes to enhanced chemoresistance of CML cells to imatinib by the transactivated STAT3 (Wang H et al. Oncotarget, March 2016) (epub ahead of print) |
| Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States (Padula WV et al. J Natl Cancer Inst., March 2016) (epub ahead of print) |
NUMB inactivation confers resistance to imatinib in chronic myeloid leukemia cells (Garcia-Alegría E et al. Cancer Lett, March 2016) (epub ahead of print) |
|
New methodologies in the molecular monitoring of CML |
c-MYB is a transcriptional regulator of ESPL1/separase in BCR-ABL-positive chronic myeloid leukemia (Prinzhorn W et al. Biomark Res, March 2016) (epub ahead of print) |
|
Clinical safety and efficacy of nilotinib or dasatinib in patients with newly diagnosed chronic-phase chronic myelogenous leukemia and pre-existing liver and/or renal dysfunction |
Next generation sequencing-assisted DNA-based digital PCR for a personalized approach to the detection and quantification of residual disease in chronic myeloid leukemia patients |
| Present and future of molecular monitoring in chronic myloid leukaemia (Soverini S et al. Br J Haematol, March 2016) (epub ahead of print) |
Next generation sequencing-assisted DNA-based digital PCR for a personalized approach to the detection and quantification of residual disease in chronic myeloid leukemia patients (Alikian M et al. J Mol Diagn, March 2016) |
| Is cure for chronic myeloid leukemia possible in the tyrosine kinase inhibitors era? (Bansal A et al. Curr Opin Hematol, March 2016) (epub ahead of print) |
|
|
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial |
|
| February 2016 | |
| Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP: The ENRICH study (Cortes JE et al. Clin Lymphoma Myeloma Leuk, February 2016) (epub ahead of print) |
High CIP2A levels correlates with an antiapoptoic phenotype that can be overcome by targeting BCL-XL in chronic meyloid leukemia (Lucas CM et al. Leukemia, February 2016) (epub ahead of print) |
| Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia (Caldemeyer L et al. Curr Hematol Malig Rep, February 2016) (epub ahead of print) |
Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib resistance preventing rpS6 phosphorylation in chronic meyloid leukaemia cells: new combined therapeutic strategies |
| Hematologic malignancies in pregnancy: Management guidelines from an international consensus (Lishner M et al. J Clin Oncol, February 2016) |
BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukemia (Latham S et al. J Clin Pathol, February 2016) (epub ahead of print) |
|
Quality of life and long-term therapy in patients with chronic myeloid leukemia |
Hsp90 inhibitor, BIIBo21, induces apoptosis and authopagy by regulating mTOR-UIIK1 pathway in imatinib-sensitive and-resistant chronic myeloid leukemic cells (He W et al. Int J Oncol, February 2016) |
|
Omacetaxine Mepesuccinate for chronic myeloid leukemia |
Normal ABL1 is a tumour suppressor and therapeutic target in human and mouse leukemias expressing oncogeneic ABL1 kinase (Dasgupta Y et al. Blood, February 2016) |
| Analysis of 2013 European LeukemiaNET (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcome (Jain P et al. Br. J Hematol, February 2016) |
Heterogeneity of leukemia-initiating capacity of chronic meylogenous leukemic stem cells (Zhang B et al. J Clin Invest, February 2016) (epub ahead of print) |
| Chronic Myeloid Leukemia: 2016 update on diagnosis, therapy and monitoring (Jabbour E et al. Am J Hematol, February 2016) |
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients (Deiniger MW et al. Blood, February 2015) |
| Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response and overall survival: A systemic review and meta-analysis (Douxfils J et al. JAMA Oncol, February 2016) (epub ahead of print) |
The role of microRNAs in the pathogenesis and drug resistance of chronic myelogenous leukemia (Review (Di Stefano C et al. Oncol Rep, February 2016) |
| The reality of cancer treatment in a developing country: the effects of delayed TKI treatment on survival, cytogenetic and molecular responses in chronic myeloid leukaemia patients (Kurtovic-Kozaric A et al. Br J Haematol, February 2016) (epub ahead of print) |
|
| Allogeneic transplantation for CML in the TKI era: striking the right balance (Innes AJ et al. Nat Rev Clin Oncol, February 2016) |
|
| January 2016 | |
| Conditional survival with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors (Sasaki K et al. Cancer, January 2016) |
The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib (Parker WT et al. Blood, January 2016) (epub ahead of print) |
| Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France intergroup des leucémies myéloides chroniques (Rea D et al. Bull Cancer, January 2016) |
Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia (Tanrikulu Simsek E et al. J Clin Pathol, January 2016) |
| Dasatinib first-line: Multicentric Italian experience outside clinical trials (Breccia M et al. Leuk Res, January 2016) |
Impact of BCR-ABL transcript type on response and survival in patients with chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors (epub ahead of print) |
| Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia (Pfirrmann M et al. Leukemia, January 2016) |
Identification and characterization of tyrosine kinase nonreceptor 2 mutations in leukemia through integration of kinase inhibitor screening and genomic analysis |
| Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase myeloid leukaemia resistant or intolerant to imatinib (Brümmendorf TH et al. Br J Haematol, January 2016) (epub ahead of print) |
In silico identifcation of inhibitors against mutated BCR-ABL protein screening and molecular dynamics simultation study (Kumar H et al. J Biomol Struct Dyn, January 2016) (epub ahead of print) |
| Conditioned survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors (Sasaki K et al. Cancer, January 2015) |
|
| Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase (Akard LP et al. Leuk Lymphoma, January 2016) (epub ahead of print) |
|
Would you like to suggest an interesting paper or article? >> Please provide us with the details here and we will be happy to review your suggestion!
Search for more publications on CML at PubMed.gov
